C22orf34 Inhibitors
Chemical inhibitors of C22orf34 target various signaling pathways and enzymes to impede its function. The inhibition mechanisms provided by these chemicals are diverse, reflecting the broad range of cellular processes C22orf34 is likely involved in. PIK-75 and LY294002, both phosphoinositide 3-kinase (PI3K) inhibitors, directly target PI3K, thereby disrupting the downstream signaling pathways, including AKT activation, which are necessary for C22orf34 activity. Wortmannin, another PI3K inhibitor, also obstructs the same pathway, ensuring a comprehensive blockade of this axis of cellular signaling. Meanwhile, PD173074, by selectively inhibiting the fibroblast growth factor receptor (FGFR), halts the differentiation and proliferation signals that C22orf34 may be a part of. Similarly, Y-27632's inhibition of ROCK, and SP600125's targeting of JNK, interfere with the Rho/ROCK and stress response pathways, respectively, which C22orf34 may be functionally linked to.
Further, SB431542 and Dorsomorphin impede the TGF-β and BMP signaling pathways by inhibiting their respective receptors, which could be crucial for the regulatory roles that C22orf34 fulfills. In contrast, Rapamycin exerts its inhibitory effects on mTOR signaling, a central regulator of cell growth and proliferation, potentially affecting C22orf34's activity in these processes. The Aurora kinase inhibitor ZM-447439 disrupts cell division mechanics, which C22orf34 may be implicated in, by impeding chromosome alignment and segregation. Lastly, U0126 and PD98059, both MEK inhibitors, suppress the MAPK/ERK pathway, a key route for cell cycle regulation and differentiation, possibly curbing the functional scope of C22orf34. These chemical inhibitors constitute a comprehensive arsenal targeting the multifaceted nature of C22orf34's involvement in cellular function.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PIK-75, hydrochloride | 372196-77-5 | sc-296089 sc-296089A | 1 mg 5 mg | $28.00 $122.00 | ||
PIK-75 is an inhibitor of phosphoinositide 3-kinase (PI3K), which is critical for numerous cellular processes, including those that could engage C22orf34. By inhibiting PI3K, PIK-75 can lead to a decrease in downstream signaling pathways that are necessary for the functional activity of C22orf34. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074 selectively inhibits the fibroblast growth factor receptor (FGFR), which is involved in cellular differentiation and proliferation. C22orf34 may be functionally linked to these processes, and inhibition of FGFR can disrupt the pathways that enable C22orf34's activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK (Rho-associated protein kinase), which is part of Rho/ROCK signaling. This pathway is implicated in various cellular functions that may include C22orf34's activity. Inhibition of ROCK can impair the pathway's function, indirectly inhibiting C22orf34. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is an inhibitor of the TGF-β receptor, affecting the SMAD signaling pathway. Given that C22orf34 is involved in cellular processes that could be regulated by TGF-β signaling, SB431542 can indirectly inhibit C22orf34 by blocking this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor, similar to PIK-75. It also impairs the PI3K/AKT pathway, which is involved in cell survival and metabolism. Inhibition of PI3K/AKT signaling can therefore disrupt processes in which C22orf34 is functionally involved. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the c-Jun N-terminal kinase (JNK), which plays a role in stress responses and apoptosis. If C22orf34 is functionally involved in these cellular responses, JNK inhibition by SP600125 could lead to its functional inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are part of the MAPK/ERK pathway. This pathway is involved in cell cycle regulation and differentiation, and C22orf34's function may be reliant on this signaling. Inhibiting MEK can thus indirectly inhibit C22orf34. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
Dorsomorphin inhibits BMP signaling by targeting the BMP type I receptors ALK2, ALK3, and ALK6. Since C22orf34 is involved in pathways influenced by BMP signaling, dorsomorphin can lead to functional inhibition of C22orf34. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor, which plays a central role in cell growth and proliferation. mTOR signaling may intersect with C22orf34's function, and inhibition by rapamycin can result in indirect inhibition of C22orf34. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor, which affects cell division by disrupting chromosome alignment and segregation. As C22orf34 may be implicated in cell cycle processes, its functional activity can be inhibited by blocking Aurora kinase. | ||||||